Related Experiment Video
Updated: Jul 31, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Primary intestinal lymphangiectasia successfully treated with octreotide
G Kuroiwa1, T Takayama, Y Sato
1Fourth Department of Internal Medicine, Sapporo Medical University, Japan.
Journal of Gastroenterology
|March 3, 2001
Summary
Octreotide therapy effectively managed a patient with protein-losing enteropathy due to primary intestinal lymphangiectasia when other treatments failed. This approach provided sustained remission for refractory cases.
Area of Science:
- Gastroenterology
- Internal Medicine
Background:
- Protein-losing enteropathy (PLE) is a condition characterized by excessive protein loss through the gastrointestinal tract.
- Primary intestinal lymphangiectasia (PIL) is a rare cause of PLE, often presenting with edema and hypoalbuminemia.
Observation:
- A 21-year-old male with PLE due to PIL experienced symptom exacerbation despite dietary changes and total parenteral nutrition (TPN).
- Initiation of octreotide therapy led to significant clinical improvement, including resolution of diarrhea, edema, hypoproteinemia, and hypoalbuminemia.
- Endoscopic, scintigraphic, and histological evaluations confirmed the positive response to octreotide treatment.
Findings:
- Octreotide therapy demonstrated efficacy in alleviating symptoms and biochemical abnormalities in a patient with refractory primary intestinal lymphangiectasia.
- Discontinuation of octreotide resulted in symptom recurrence, while re-initiation led to sustained remission, highlighting its therapeutic role.
- The study suggests octreotide is a viable treatment option for challenging cases of primary intestinal lymphangiectasia.
Implications:
- Octreotide represents a potential therapeutic modality for managing refractory primary intestinal lymphangiectasia and associated protein-losing enteropathy.
- This case underscores the importance of considering novel therapeutic agents when standard treatments for rare gastrointestinal disorders prove insufficient.
- Further research into the mechanisms and broader application of octreotide in PLE is warranted.
